Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
Phase 4
Recruiting
- Conditions
- Hepatocellular CarcinomaHepatocellular Cancer
- Interventions
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 24
- Registration Number
- NCT05185505
- Locations
- 🇺🇸
Houston Methodist Research Institute, Houston, Texas, United States
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
Phase 2
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Procedure: Transcatheter Arterial Chemoembolization
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 50
- Registration Number
- NCT05171335
- Locations
- 🇺🇸
Houston Methodist Research Institute, Houston, Texas, United States
Opioid Use After Thyroid and Parathyroid Surgeries
Not Applicable
Completed
- Conditions
- ThyroidectomyOpioid UseParathyroidectomyPain, Postoperative
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 240
- Registration Number
- NCT04955444
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy
Phase 1
Terminated
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 13
- Registration Number
- NCT04911166
- Locations
- 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
Mapping of the Human Brainstem During Continence and Micturition: Noninvasive 7-T fMRI Study
Completed
- Conditions
- Healthy
- First Posted Date
- 2021-04-15
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04846387
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans with Kidney Transplant
Phase 4
Active, not recruiting
- Conditions
- Acute Rejection of Renal TransplantDonor Specific AntibodiesKidney Disease, End-Stage
- Interventions
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 46
- Registration Number
- NCT04665310
68 Ga-PSMA for High Risk Prostate Cancer
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 80
- Registration Number
- NCT04614363
- Locations
- 🇺🇸
Houston Methodist, Houston, Texas, United States
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)
Phase 1
- Conditions
- Covid19
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 350
- Registration Number
- NCT04554992
- Locations
- 🇺🇸
Houston Methodist Hopsital, Houston, Texas, United States
Blood Flow Restriction Training for The Shoulder
Not Applicable
Completed
- Conditions
- Healthy
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 69
- Registration Number
- NCT04540367
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Motion Capture: Baseball Swing
Completed
- Conditions
- Elbow Force
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 16
- Registration Number
- NCT04503070
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States